Minerva Neurosciences Receives Unexpected Regulatory Setback as FDA Issues Complete Response Letter for Innovative Schizophrenia Treatment
BURLINGTON, Mass., Feb. 27, 2024 - Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for central nervous system disorders, has recently e...
Feb 27, 2024
• Major Pharmaceutical Preparations Industry
Product Service News
Minerva Neurosciences
